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A B S T R A C T
Elizabethkingia meningoseptica is a nonfermentative gram-negative bacillus that is ubiquitously found in
hospital environments and as such, it has been associated with various nosocomial infections.
Immunocompromised individuals are particularly at increased risk for developing severe infections due
to E. meningoseptica, including bacteremia. E. meningoseptica is resistant to multiple antimicrobials
commonly used for gram-negative bacteria and conventional empirical antimicrobials targeting those
organisms may result in unfavorable outcome. We report a case of bacteremia due to E. meningoseptica in
a patient who necessitated chronic hemodialysis therapy to heighten awareness of this emerging
pathogen among patients on hemodialysis.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Elizabethkingia meningoseptica, previously known as Chryseo-
bacterium meningosepticum, is a gram-negative bacillus that is
widely distributed in nature [1]. E. meningoseptica was originally
described as Flavobacterium meningosepticum in 1959 by an
American bacteriologist Elizabeth O. King [2]. It is ubiquitously
found in soil and water and it has also been recovered from
hospital environments. E. meningoseptica is nonmotile, oxidase-
positive and a medically important nonfermentative gram-
negative bacillus that has been associated with a broad range of
infectious etiologies, notably outbreaks of neonatal meningitis
[3,4]. In adults, E. meningoseptica can also cause pneumonia,
endocarditis, and bacteremia primarily in immunocompromised
individuals [5,6]. For instance, in a study of 118 cases of
E. meningoseptica bacteremia, the most common underlying
predisposing conditions were malignancies (36%) and diabetes
mellitus (25%) [7]. Recognition of E. meningoseptica is paramount
for clinicians since multi-drug resistance is common for this
organism. We report a case of bacteremia due to E. meningoseptica
in a patient who necessitated chronic hemodialysis therapy
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A 68-year-old male with a history of diabetes mellitus,
hypertension, and end-stage renal disease was in his usual status
until ﬁve days prior to presentation when he developed fatigue,
anorexia and fevers. Hemodialysis had been initiated 33 years
before due to his progressive diabetic nephropathy. The patient’s
medical history was otherwise unremarkable and he was up-to-
date with his annual physical evaluation. On physical examination,
the patient appeared ill. The temperature was 101.0 8F, blood
pressure 103/64 mm Hg, pulse 107 beats per minute, respirations
21 breaths per minute and oxygen saturation 97% on room air. His
heart sounds revealed tachycardia without murmurs and his lungs
disclosed crackles on the right side. Laboratory studies revealed a
white blood cell count of 10,800 cells/mm3 with 87% polymorpho-
nuclear leukocytes, hemoglobin of 10.5 g/dL, and platelets of
214,000 mm3. The level of sodium was 137 mmol/L, potassium
4.4 mmol/L, bicarbonate 20 mEq/L, urea nitrogen 31 mg/dL, and
creatinine 2.3 mg/dL. Two sets of cultures of the blood obtained
through the hemodialysis catheter at the time of admission grew
gram-negative bacilli after 48 h of incubation. Another two sets of
the blood cultures collected through a peripheral vein also grew
gram-negative bacilli. The blood agar demonstrated multiple yellow
pigmented colonies. The organism was nonmotile, oxidase and
indole positive. Subsequently, it was identiﬁed as E. meningoseptica
based on further biochemical reactions and automated bacteriol-
ogy identiﬁcation system in the laboratory. The patient was
treated with intravenous vancomycin for 4 weeks based on the
susceptibility results; the isolate was considered susceptible toe under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
T. Shinha, R. Ahuja / IDCases 2 (2015) 13–1514vancomycin with a Minimal Inhibitory Concentration (MIC)
value of 1 mg/mL using broth microdilution methodology. The
hemodialysis catheter was removed and the catheter tip sent for
culture demonstrated no growth. The patient became afebrile
and his subsequent blood cultures remained sterile.
Discussion
E. meningoseptica is ubiquitously found in soil and water.
Because of its survival in hospital environments, nosocomial
outbreaks can occur as a result of exposure to a contaminated
water source or medical devices. Notably, it has been reported to
cause neonatal meningitis associated with nosocomial out-
breaks [3,4]. In adults, most infections due to E. meningoseptica
are also nosocomial, particularly affecting immunocompro-
mised individuals. Potential risk factors for developing
E. meningoseptica bacteremia identiﬁed in the literature include
malignancies, steroid use, diabetes mellitus, neutropenia, and
organ transplant [7,8]. Our patient had a longstanding history of
diabetic nephropathy which necessitated chronic hemodialysis
therapy. Importantly, E. meningoseptica bacteremia has been
described in patients with a wide array of renal pathology which
required chronic hemodialysis therapy [9–14]. Our patient
potentially developed catheter-related bacteremia considering
its ability to contaminate medical devices and the blood
cultures positive for E. meningoseptica through the hemodialysis
catheter.
Optimal antimicrobial guidelines to treat E. meningoseptica
remain to be established. It is usually resistant to many antibiotics
commonly used to treat infections caused by gram-negative
bacteria. It is generally resistant to aminoglycosides, and b-lactam
agents, including carbapenems, due to the production of extended
spectrum b-lactamases (ESBL) and metallo-b-lactamases [15]. In
contrast, E. meningoseptica is often susceptible to agents used for
gram-positive bacteria. Vancomycin has been described as an
active agent against E. meningoseptica [16,17], particularly in
cases of infantile meningitis due to E. meningoseptica [18,19].
However, contradictory results with high vancomycin MIC
values against E. meningoseptica have also been reported
[20,21]. Rifampin is potentially effective when used as part of
combination therapy [17,22]. Although the advanced molecular
techniques have become available to detect drug resistant genes
for metallo-b-lactamase and ESBL, the mechanism of action of
antimicrobial agents used for gram-positive bacteria against E.
meningoseptica has not been well described in the literature
[23,24]. Currently, validated susceptibility testing methods are
not available and MIC breakpoints have not been established by
the Clinical and Laboratory Standards Institute (CLSI) for E.
meningoseptica. Results of susceptibility testing may vary
substantially when different methods are used. In general,
broth microdilution methodology is more reliable than disk
diffusion technique [13].
Conclusions
E. meningoseptica is ubiquitously found in hospital environ-
ments. It has been associated with severe nosocomial infections
related to contaminated medical devices. Therefore, when E.
meningoseptica is isolated from clinical specimens, its pathogenic
potential associated with clinical signiﬁcance should be thorough-
ly evaluated. Bacteremia due to E. meningoseptica primarily occurs
in immunocompromised individuals, including those with various
nephropathy which necessitated hemodialysis therapy. Recogni-
tion of E. meningoseptica is of critical importance for clinicians since
conventional empirical treatment against gram-negative bacteriamay result in unfavorable outcome given its unique antimicrobial
susceptible pattern.
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